← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Aptitude Medical Systems, Inc.
Santa Barbara, CA
$11,962,275
Total funding
18
Grants
Funding over time
peak $2.6M · FY2014–23$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$11,962,275 · 18
By mechanism
R44$9,256,751 · 7
R43$2,705,524 · 11
Investigators at Aptitude Medical Systems, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Scalable High Quality Aptamer Generation via Chemically-Augmented Particle Display$918,746
R44 · FY2018 · GM
Targeting SDF-1 for effective wet AMD treatment$911,698
R44 · FY2020 · EY
Particle display: a new paradigm in high throughput discovery of ultra-high perfo$872,697
R44 · FY2015 · GM
Targeting SDF-1 for effective wet AMD treatment$805,217
R44 · FY2021 · EY
Real-time Point of Care Insulin Monitoring Device for Improved Diabetes Management$792,839
R44 · FY2017 · DK
Fully modified bispecific aptamer for effective combination therapy of neovascular ocular diseases$755,521
R44 · FY2023 · EY
Fully modified bispecific aptamer for effective combination therapy of neovascular ocular diseases$744,393
R44 · FY2022 · EY
Real-time Point of Care Insulin Monitoring Device for Improved Diabetes Management$640,326
R44 · FY2018 · DK
Particle display: a new paradigm in high throughput discovery of ultra-high perfo$625,303
R44 · FY2016 · GM
Scalable High Quality Aptamer Generation via Chemically-Augmented Particle Display$534,143
R44 · FY2019 · GM
Sustained release of next-generation aptamers to treat wet AMD$299,693
R43 · FY2018 · EY
Next-generation aptamers for faster, safer, more sensitive in vivo PET imaging$299,544
R43 · FY2017 · EB
Topical delivery of therapeutic aptamers$293,239
R43 · FY2018 · EB
Targeting SDF-1 for effective wet AMD treatment$282,661
R44 · FY2019 · EY
Targeting SDF-1 for effective wet AMD treatment$250,102
R43 · FY2017 · EY
Developing multi-specific aptamers for safe, potent, and long-lasting treatment of geographic atrophy$247,641
R44 · FY2022 · EY
Scalable High Quality Aptamer Generation via Chemically-Augmented Particle Display$227,400
R44 · FY2018 · GM
Fully modified bispecific aptamer for effective combination therapy of neovascular ocular diseases$224,973
R44 · FY2020 · EY
Targeting PDGFs for Potential Treatment of Proliferative Vitreoretinopathy$224,946
R43 · FY2019 · EY
Particle display: a new paradigm in high throughput discovery of ultra-high perfo$224,700
R44 · FY2014 · GM